Why is Astrazeneca Phar falling/rising?

As of 06-Oct, Astrazeneca Pharma India Ltd is experiencing a price increase, currently at ₹9,360.00, reflecting a rise of ₹35.3 or 0.38%. The stock has shown strong performance recently, gaining 6.13% over the last five days and outperforming its sector by 0.27%. It is trading above all its moving averages, indicating positive momentum. Over the past year, Astrazeneca has delivered a return of 26.22%, significantly outperforming the BSE500 index. The company has also reported positive financial results for the last three consecutive quarters, with a notable growth in profit after tax and net sales, which supports the stock's upward movement. However, it is important to note that there has been a decline in investor participation, with delivery volume dropping by 40.05% compared to the five-day average.
In the broader market context, Astrazeneca's short-term return of 5.33% over the past week outpaces the Sensex's 1.77% increase, highlighting its strong performance relative to the market. The company's high management efficiency, characterized by a return on equity of 20.34% and a low debt-to-equity ratio, further bolsters investor confidence. However, the stock is considered expensive, trading at a premium compared to its peers, which may pose risks for future valuation adjustments. Despite these concerns, the consistent returns over the past three years and the majority ownership by promoters suggest a stable outlook, contributing to the stock's current rise.